Remarks on a Cutaneous Affection, prodused by cretain Poisonous Vagetables

Dakin, Richard L.

doi:10.1097/00000441-182905000-00010

Cited by 60 publications

(15 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The field of oral tolerance dates back to 1829 when Dakin [1] demonstrated the efficacy of chewing the leaves of the poison ivy plant to prevent painful skin rashes from contact with the plant. In historical documentation, one can find a similar practice among American Indians and habitants of Central Asia long before it was described in the scientific literature.…”

Section: Introductionmentioning

confidence: 99%

Oral tolerance and gut-oriented immune response to dietary proteins

Alpan

2001

Curr Allergy Asthma Rep

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Oral tolerance and gut-oriented immune response to dietary proteins

Alpan

2001

Curr Allergy Asthma Rep

View full text Add to dashboard Cite

“…Although induction of tolerance to orally administered antigens has been recognized for a long time, its potential for treatment of autoimmunity and graft rejection has recently generated renewed interest (1)(2)(3)(4). Oral administration of autoantigens suppresses a variety of experimental autoimmune diseases, including experimental autoimmune encephalomyelitis, (EAE)' collagen and adjuvant-induced arthritis, diabetes in the non-obese diabetic mouse and experimental autoimmune uveoretinitis (EAU) (4).…”

Section: Introductionmentioning

confidence: 99%

Interleukin-2 treatment potentiates induction of oral tolerance in a murine model of autoimmunity.

Rizzo

Miller-Rivero²,

Chan³

et al. 1994

J. Clin. Invest.

View full text Add to dashboard Cite

The present study addresses the feasibility of potentiating oral tolerance by immunomanipulation, using the murine model of experimental autoimmune uveoretinitis (EAU) induced by immunization with the retinal antigen interphotoreceptor retinoid binding protein (IRBP). Three feedings of 0.2 mg IRBP every other day before immunization did not protect against EAU, whereas a similar regimen of five doses was protective. However, supplementing the nonprotective 3x regimen with as little as one injection of 1,000 U of human recombinant interleukin-2 (IL-2) resulted in disease suppression that was equal to that of the protective 5x regimen. The protective effect was maintained across a range of IL-2 doses and times of administration; none of the IL-2 regimens tested resulted in disease enhancement. Peyer's Patch cells of 3X-fed and IL-2-treated mice showed greatly increased production of TGF-fl, IL-4, and IL-10 compared with animals given the nonprotective 3x regimen and to animals given the protective 5x regimen. We propose that IL-2 treatment enhances protection from EAU at least in part by stimulating production of antiinflammatory cytokines by regulatory cells in Payer's Patches. Moreover, the observed lymphokine production patterns suggest that whereas protection induced by the 3x + IL-2 regimen is likely to involve antiinflammatory cytokines, protection induced by the 5X regimen might involve anergy or deletion of the uveitogenic T cells. These results could have practical implications for use of IL-2 as a safe and effective way of potentiating oral tolerance. (J. Clin. Invest. 1994. 94:1668-1672

show abstract

“…It's roots seem to be in the ideas of homeopathy that was very popular at that time ('fight similar with similar') [18], and anecdotal reports of American Indians avoiding Rhus dermatitis by chewing the leaves of the plants [19], which could not be confirmed by later systematic research [20]. Further inspiration seems to have come from early reports about successful therapy of hay fever by means of allergy vaccination [21,22].…”

Section: Hapten Immunotherapy: the Origin Of The Ideamentioning

confidence: 99%

Immunotherapy of Allergic Contact Dermatitis

Śpiewak

2011

Immunotherapy

View full text Add to dashboard Cite

The term 'immunotherapy' refers to treating diseases by inducing, enhancing or suppressing immune responses. As allergy is an excessive, detrimental immune reaction to otherwise harmless environmental substances, immunotherapy of allergic disease is aimed at the induction of tolerance toward sensitizing antigens. This article focuses on the historical developments, present state and future outlook for immunotherapy with haptens as a therapeutic modality for allergic contact dermatitis. Inspired by the effectiveness of immunotherapy in respiratory allergies, attempts were undertaken at curing allergic contact dermatitis by means of controlled administration of the sensitizing haptens. Animal and human experiments confirmed that tolerance to haptens can be induced most effectively when the induction of tolerance precedes attempted sensitization. In real life, however, therapy is sought by people who are already sensitized and an effective reversal of hypersensitivity seems more difficult to achieve. Decades of research on Rhus hypersensitivity led to a conclusion that immunotherapy can suppress Rhus dermatitis, however, only to a limited degree, for a short period of time, and at a high risk of side effects, which makes this method therapeutically unprofitable. Methodological problems with most available studies of immunotherapy of contact allergy to nickel make any definite conclusions impossible at this stage.

show abstract

Remarks on a Cutaneous Affection, prodused by cretain Poisonous Vagetables

Cited by 60 publications

References 0 publications

Oral tolerance and gut-oriented immune response to dietary proteins

Oral tolerance and gut-oriented immune response to dietary proteins

Interleukin-2 treatment potentiates induction of oral tolerance in a murine model of autoimmunity.

Immunotherapy of Allergic Contact Dermatitis

Contact Info

Product

Resources

About